A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 66
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : ASCOT
Long Form : Anglo-Scandinavian Cardiac Outcomes Trial
No. Year Title Co-occurring Abbreviation
2018 Genetic variants in PPARGC1B and CNTN4 are associated with thromboxane A2 formation and with cardiovascular event free survival in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). SNPs, TXB2
2018 Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. BPLA, HR, LLA
2018 Relationship of Inter-Individual Blood Pressure Variability and the Risk for Recurrent Stroke. BPV, TIA
2017 Risk for Incident Heart Failure: A Subject-Level Meta-Analysis From the Heart "OMics" in AGEing (HOMAGE) Study. Health ABC, HF, HOMAGE, PREDICTOR, PROSPER
2016 Circulating Apolipoprotein E Concentration and Cardiovascular Disease Risk: Meta-analysis of Results from Three Studies. APOE, CVD, ELSA, NPHSII, OR
2016 High Serum Immunoglobulin G and M Levels Predict Freedom From Adverse Cardiovascular Events in Hypertension: A Nested Case-Control Substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. CHD, CRP, CV, FRS, MDA-LDL, NT-pro-BNP, OR, SD
2016 VARIABILTY OF ARTERIAL PRESSURE AND RENAL FUNCTION. VAP
2015 Combination therapy in the extended cardiovascular continuum: a focus on perindopril and amlodipine. ACE, BP, CCBs, RAAS
2015 Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials. CARDS, CV, LDL, SPARCL, TNT
10  2014 Combination of statin plus renin angiotensin system inhibition for the prevention or the treatment of atherosclerotic cardiovascular disease. ATTEMPT, CVD, GREACE, JCAD, miRs, RAS
11  2014 Excess pressure integral predicts cardiovascular events independent of other risk factors in the conduit artery functional evaluation substudy of Anglo-Scandinavian Cardiac Outcomes Trial. CAFE
12  2014 The value of N-terminal pro-B-type natriuretic peptide in determining antihypertensive benefit: observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). NT-proBNP
13  2013 Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm. CI, CRP, CV, HR, HR, LDL-C
14  2013 Genome-wide analysis of blood pressure variability and ischemic stroke. GWAS, vBP
15  2012 Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial. CI, CV, LDL-C, OR, SD
16  2012 Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). CARDS, CVD, GWAS, PROSPER, SNP
17  2012 Is plasma renin activity a biomarker for the prediction of renal and cardiovascular outcomes in treated hypertensive patients? Observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). AHT, BB, CCB, CHD, CIs, CV, OR, PRA
18  2011 Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk. ---
19  2011 Efficacy of Sevikar compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: Rationale and design of the SEVITENSION study. CABP, CAFE
20  2011 Ethnic variations in lipid-lowering in response to a statin (EVIREST): a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). ASCOT-LLA, EVIREST, HDL, LDL
21  2010 Differential effects of antihypertensive treatment on left ventricular diastolic function: an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy. BNP, BP, HACVD, LV
22  2010 High adherence and concordance within a clinical trial of antihypertensives. ---
23  2010 Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension? GITS
24  2010 Tissue Doppler E/E' ratio is a powerful predictor of primary cardiac events in a hypertensive population: an ASCOT substudy. ---
25  2010 Wave reflection predicts cardiovascular events in hypertensive individuals independent of blood pressure and other cardiovascular risk factors: an ASCOT (Anglo-Scandinavian Cardiac Outcome Trial) substudy. BP, WRI
26  2010 [Utility of combined therapy in the prevention and treatment of the cardiovascular disease]. ---
27  2009 Atorvastatin treatment is associated with less augmentation of the carotid pressure waveform in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT). ASCOT-LLA
28  2009 Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). TCVP
29  2009 Circulating levels of adiponectin, leptin, and tumour necrosis factor alpha in hypertension. CVD, TNF
30  2009 Coronary heart disease benefits from blood pressure and lipid-lowering. BPLA, CHD, LLA
31  2009 Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study. CAFE-LLA, CI
32  2009 Serum amyloid A, C-reactive protein, and retinal microvascular changes in hypertensive diabetic and nondiabetic individuals: an Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) substudy. CRP, SAA
33  2009 Statin therapy and risk of developing type 2 diabetes: a meta-analysis. CORONA, HPS, LIPID, RRs, WOSCOPS
34  2009 The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1. NICE
35  2008 Ethnicity and left ventricular diastolic function in hypertension an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy. ---
36  2007 Prognostic value of plasma soluble P-selectin and von Willebrand factor as indices of platelet activation and endothelial damage/dysfunction in high-risk patients with hypertension: a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial. DM
37  2007 Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy. ---
38  2006 "Anti-inflammatory" drugs and their effects on type 2 diabetes. ACE, WOSCOPS
39  2006 Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. BP, CAFE
40  2006 Perindopril. PREAMI, PROGRESS
41  2006 Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. CHD, LLA
42  2006 The effect of antihypertensive agents on new-onset diabetes mellitus: time to amend the guidelines? CCBs
43  2005 A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus? CARDS, CARE, DAIS, HDL-C, HPS, LDL-C
44  2005 Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)]. TOD, VEGF
45  2005 Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)? ASCOT-LLA, CHD, HMG-CoA, MI
46  2005 Statins and LDL-cholesterol lowering: an overview. CARDS, CHD, CRP, HDL-C, LDL-C, REVERSAL
47  2005 Therapeutic controversies in hypertension. ---
48  2005 [First evidence of greater cardiovascular protective effects of newer as compared to old antihypertensive drugs treatments: the ASCOT-BPLA results]. ---
49  2004 Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). ECM, MMP
50  2004 Platelet and haemorheological markers in 'high risk' hypertensives are improved by tighter blood pressure control and cardiovascular risk management: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). BP, FIB, Hct, PV, WBC
51  2004 Platelet indexes in relation to target organ damage in high-risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). beta-TG, pP-sel, sP-sel, TOD
52  2004 Relationship of homocysteine to markers of platelet and endothelial activation in "high risk" hypertensives: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. BP, Hcy, HPLC, vWF
53  2004 Treating to hypertension targets. BHS
54  2004 [Statin therapy for hypertensive patients]. ---
55  2003 Clinical trials: Evidence and unanswered questions--hypertension. ACE, CCBs, HDFP, MRFIT
56  2003 Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. CARDS
57  2003 Physical activity in relation to indices of endothelial function and angiogenesis factors in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). FMD, VEGF, vWF
58  2003 Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT]). FMD, TF, VEGF, vWF
59  2002 Answering the unanswered questions: ongoing trials of statins and antihypertensives in type 2 diabetes. CCBs, CHD
60  2002 Lipid lowering in hypertension and heart protection: observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) and the Heart Protection Study. ---
61  2002 Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). sP-sel, TOD, vWF
62  2001 Cardiovascular risk factors in a cohort of 30,000 high-risk men and women in the UK: cross-sectional, retrospective and prospective studies of screenees for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). ---
63  2001 Health economics of prevention of coronary heart disease and vascular events: a cost-effectiveness analysis based on the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). ---
64  2000 Coronary heart disease prevention As the primary goal in contemporary trials in the treatment of hypertension. ---
65  2000 Does the Dundee Step Test predict outcome in treated hypertension? A sub-study protocol for the ASCOT trial. Anglo-Scandinavian Cardiac Outcome Trial. BP
66  2000 [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials]. AASK, CONVINCE, NORDIL, PREVENT, Syst-Eur